ID: ALA472783

Max Phase: Preclinical

Molecular Formula: C10H15N2O9P

Molecular Weight: 338.21

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(=O)[nH]c(=O)n1[C@@H]1O[C@H](COP(=O)(O)O)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C10H15N2O9P/c1-4-2-6(13)11-10(16)12(4)9-8(15)7(14)5(21-9)3-20-22(17,18)19/h2,5,7-9,14-15H,3H2,1H3,(H,11,13,16)(H2,17,18,19)/t5-,7-,8-,9-/m1/s1

Standard InChI Key:  CHBBJHPQYVYKFI-ZOQUXTDFSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 338.21

Molecular Weight (Monoisotopic): 338.0515

AlogP: -2.43

#Rotatable Bonds: 4

Polar Surface Area: 171.31

Molecular Species: ACID

HBA: 8

HBD: 5

#RO5 Violations: 0

HBA (Lipinski): 11

HBD (Lipinski): 5

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 1.23

CX Basic pKa:

CX LogP: -2.34

CX LogD: -5.87

Aromatic Rings: 1

Heavy Atoms: 22

QED Weighted: 0.37

Np Likeness Score: 0.77

References

1. Bello AM, Poduch E, Liu Y, Wei L, Crandall I, Wang X, Dyanand C, Kain KC, Pai EF, Kotra LP..  (2008)  Structure-activity relationships of C6-uridine derivatives targeting plasmodia orotidine monophosphate decarboxylase.,  51  (3): [PMID:18189347] [10.1021/jm7010673]

2. Bello AM, Konforte D, Poduch E, Furlonger C, Wei L, Liu Y, Lewis M, Pai EF, Paige CJ, Kotra LP..  (2009)  Structure-activity relationships of orotidine-5'-monophosphate decarboxylase inhibitors as anticancer agents.,  52  (6): [PMID:19260677] [10.1021/jm801224t]

Source

Source(1):

• Scientific Literature